Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent

Mark Welliver; John McDonough; Nicholas Kalynych; Robert Redfern

doi:10.2147/dddt.s2757

Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent

Mark Welliver
, John McDonough
, Nicholas Kalynych
, Robert Redfern

School of Nursing

Producción científica: Review article › revisión exhaustiva

Idioma original	English
Páginas (desde-hasta)	49-59
Número de páginas	11
Publicación	Drug Design, Development and Therapy
N.º	2
DOI	https://doi.org/10.2147/dddt.s2757
Estado	Published - 2008

ASJC Scopus Subject Areas

Pharmacology
Pharmaceutical Science
Drug Discovery

Acceder al documento

10.2147/dddt.s2757

Otros archivos y enlaces

Citar esto

@article{b010698f3a2b4489b023f6226e53b167,

title = "Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent",

keywords = "Encapsulation, Modified cyclodextrin, Muscle relaxants, Neuromuscular blockade reversal, Selective relaxant binding agent (SRBA), Sugammadex",

author = "Mark Welliver and John McDonough and Nicholas Kalynych and Robert Redfern",

year = "2008",

doi = "10.2147/dddt.s2757",

language = "English",

pages = "49--59",

number = "2",

}

TY - JOUR

T1 - Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent

AU - Welliver, Mark

AU - McDonough, John

AU - Kalynych, Nicholas

AU - Redfern, Robert

PY - 2008

Y1 - 2008

KW - Encapsulation

KW - Modified cyclodextrin

KW - Muscle relaxants

KW - Neuromuscular blockade reversal

KW - Selective relaxant binding agent (SRBA)

KW - Sugammadex

UR - https://www.scopus.com/pages/publications/67651154018

UR - https://www.scopus.com/pages/publications/67651154018#tab=citedBy

U2 - 10.2147/dddt.s2757

DO - 10.2147/dddt.s2757

M3 - Review article

AN - SCOPUS:67651154018

SP - 49

EP - 59

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

IS - 2

ER -